C-Ray Therapeutics is an innovative biopharmaceutical company devoted to the development, manufacturing, clinical application and commercialization of radiopharmaceuticals.
Based on the portfolio around life-threatening diseases such as oncology, we are bringing innovation to the development and commercialization of radiopharmaceuticals to address patients’ unmet clinical needs.
Radiopharmaceuticals are the essence of nuclear medicine and are increasingly being adopted as a key modality for targeted therapies for cancer.
Combining molecular imaging findings and targeted radio therapy has the potential of improving treatment outcomes for patients.
C-Ray Therapeutics deploys a R&D strategy fully aligned with the society’s demand for the development of medical isotopes and the company’s mission of generating clinical benefit for patients. Meanwhile, C-Ray Therapeutics is collaborating with a large network of biopharmas, research institutes, and leading experts from around the world to develop revolutionary products for patients.
C-Ray Therapeutics Announced Approval of the First Radiation Safety License for Its Chengdu Facility in ChinaMore
Talents are the cornerstone of our growth, and long-term talent development and team building as a key to our success. At C-Ray Therapeutics, we embrace people with passion and creativity to join our journey along the way.